U.S. markets close in 6 hours 23 minutes

Anebulo Pharmaceuticals, Inc. (ANEB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.97+0.39 (+5.15%)
As of 9:32AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close7.58
Open7.77
Bid7.22 x 800
Ask8.18 x 1000
Day's Range7.70 - 7.97
52 Week Range6.31 - 9.33
Volume2,601
Avg. Volume83,093
Market Cap185.432M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering

    Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) ("Anebulo" or the "Company"), a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction, today announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $7.00 per share. The gross proceeds from the offering to the Company, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to be approximately $21.0 million. In addition, the Company has granted the underwriter a 30-day option to purchase from the Company up to an additional 450,000 shares of common stock to cover over-allotments, if any, at the initial public offering price, less underwriting discounts and commissions.